VINCERX PHARMA INC (VINC) Fundamental Analysis & Valuation
NASDAQ:VINC • US92731L3042
Current stock price
0.1 USD
-0.03 (-24.98%)
At close:
0.0639 USD
-0.04 (-36.1%)
After Hours:
This VINC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. VINC Profitability Analysis
1.1 Basic Checks
- In the past year VINC has reported negative net income.
- In the past year VINC has reported a negative cash flow from operations.
- In the past 5 years VINC always reported negative net income.
- VINC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of VINC (-375.69%) is worse than 96.12% of its industry peers.
- With a Return On Equity value of -1104.04%, VINC is not doing good in the industry: 82.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -375.69% | ||
| ROE | -1104.04% | ||
| ROIC | N/A |
ROA(3y)-234.12%
ROA(5y)-147.19%
ROE(3y)-531.34%
ROE(5y)-326.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- VINC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. VINC Health Analysis
2.1 Basic Checks
- The number of shares outstanding for VINC has been increased compared to 1 year ago.
- VINC has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for VINC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -45.83, we must say that VINC is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -45.83, VINC is not doing good in the industry: 93.83% of the companies in the same industry are doing better.
- There is no outstanding debt for VINC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -45.83 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- VINC has a Current Ratio of 1.21. This is a normal value and indicates that VINC is financially healthy and should not expect problems in meeting its short term obligations.
- VINC's Current ratio of 1.21 is on the low side compared to the rest of the industry. VINC is outperformed by 85.19% of its industry peers.
- A Quick Ratio of 1.21 indicates that VINC should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.21, VINC is not doing good in the industry: 84.13% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 |
3. VINC Growth Analysis
3.1 Past
- The earnings per share for VINC have decreased strongly by -968.78% in the last year.
EPS 1Y (TTM)-968.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1726.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- VINC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.65% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.41%
EPS Next 2Y40.4%
EPS Next 3Y25.08%
EPS Next 5Y14.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. VINC Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VINC. In the last year negative earnings were reported.
- Also next year VINC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- VINC's earnings are expected to grow with 25.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.4%
EPS Next 3Y25.08%
5. VINC Dividend Analysis
5.1 Amount
- No dividends for VINC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VINC Fundamentals: All Metrics, Ratios and Statistics
0.1
-0.03 (-24.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-12 2025-05-12
Inst Owners10.77%
Inst Owner Change-47.37%
Ins Owners8.37%
Ins Owner Change0%
Market Cap523.00K
Revenue(TTM)N/A
Net Income(TTM)-30.07M
Analysts82.86
Price Target204 (203900%)
Short Float %0.02%
Short Ratio0
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)-21.11%
Max EPS beat(2)23.08%
EPS beat(4)2
Avg EPS beat(4)-15.98%
Min EPS beat(4)-141.97%
Max EPS beat(4)76.09%
EPS beat(8)5
Avg EPS beat(8)-4.73%
EPS beat(12)5
Avg EPS beat(12)-7.86%
EPS beat(16)7
Avg EPS beat(16)-3.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3233.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2508.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.19 | ||
| P/tB | 0.19 | ||
| EV/EBITDA | N/A |
EPS(TTM)-20.2
EYN/A
EPS(NY)-12.24
Fwd EYN/A
FCF(TTM)-5
FCFYN/A
OCF(TTM)-5
OCFYN/A
SpS0
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -375.69% | ||
| ROE | -1104.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-234.12%
ROA(5y)-147.19%
ROE(3y)-531.34%
ROE(5y)-326.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 | ||
| Altman-Z | -45.83 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-968.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1726.09%
EPS Next Y39.41%
EPS Next 2Y40.4%
EPS Next 3Y25.08%
EPS Next 5Y14.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.41%
OCF growth 3YN/A
OCF growth 5YN/A
VINCERX PHARMA INC / VINC Fundamental Analysis FAQ
What is the fundamental rating for VINC stock?
ChartMill assigns a fundamental rating of 2 / 10 to VINC.
What is the valuation status for VINC stock?
ChartMill assigns a valuation rating of 1 / 10 to VINCERX PHARMA INC (VINC). This can be considered as Overvalued.
Can you provide the profitability details for VINCERX PHARMA INC?
VINCERX PHARMA INC (VINC) has a profitability rating of 0 / 10.